CUP0.F Chugai Pharmaceutical Co., Ltd.

Healthcare Drug Manufacturers - General Frankfurt Exchange
19.10 EUR
Close of Nov 12, 2026
16.20 28.33
Market cap
EUR 62.9B
P/E
21.7x
P/B
5.70x
ROE
24.0%
Dividend yield
2.80%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is CUP0.F undervalued?

Graham number
Price19.10
Graham value8.15
Premium134.5%

CUP0.F trades 134.5% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Chugai Pharmaceutical Co., Ltd. fundamental analysis

No fundamental analysis for Chugai Pharmaceutical Co., Ltd. yet.

Chugai Pharmaceutical Co., Ltd. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Chugai Pharmaceutical Co., Ltd.

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept, an immunosuppressant; Enspryng, a pH-dependent binding human…

Full company profile